Hypertensive emergency with cardiac tamponade associated with hypothyroidism [0.03%]
与甲状腺功能减退相关的高血压急症合并心包填塞
Joel Handler
Joel Handler
Neurovascular compression of the medulla: can it cause neurogenic hypertension? [0.03%]
延髓的神经血管压迫可否导致神经过敏性高血压？
Thomas G Pickering
Thomas G Pickering
Konstantinos Petidis,Stella Douma,Spyros Aslanidis et al.
Konstantinos Petidis et al.
Primary aldosteronism accompanied by hypokalemia is a cause of secondary hypertension. Diagnosis of primary aldosteronism has increased dramatically in recent years with the wider availability of aldosterone and plasma renin activity measur...
John B Kostis,Philip B Gorelick,Franz H Messerli
John B Kostis
In October 2006, a panel of experts participated in a teleconference to discuss the reduction of stroke risk factors in patients at risk for stroke. The panel was chaired by John B. Kostis, MD, Professor and Chairman, Department of Medicine...
Titration of HCTZ to 50 mg daily in individuals with stage 2 systolic hypertension pretreated with an angiotensin receptor blocker [0.03%]
用于治疗收缩期2级高血压并已使用血管紧张素受体阻滞剂的个体每日接受50毫克氢氯噻嗪標记试验
Joseph L Izzo Jr,Joel M Neutel,Tonous Silfani et al.
Joseph L Izzo Jr et al.
The authors studied the combination of hydrochlorothiazide (HCTZ) 50 mg/d plus olmesartan medoxomil (OM) 40 mg/d in stage 2 systolic hypertension during an extension phase of an open-label 12-week dose titration study. Subjects whose blood ...
Randomized Controlled Trial
Journal of clinical hypertension (Greenwich, Conn.). 2007 Jan;9(1):45-8. DOI:10.1111/j.1524-6175.2007.05714.x 2007
Efficacy and safety of treating stage 2 systolic hypertension with olmesartan and olmesartan/HCTZ: results of an open-label titration study [0.03%]
奥美沙坦及奥美沙坦/氢氯噻嗪治疗2级收缩压高血压疗效和安全性：开放标记剂量递增研究结果
Joseph L Izzo Jr,Joel M Neutel,Tonous Silfani et al.
Joseph L Izzo Jr et al.
This study investigated an aggressive treatment program for stage 2 systolic hypertension (pretreatment systolic blood pressure [SBP] > or = 160 mm Hg) using the angiotensin receptor blocker olmesartan medoxomil (OM) and hydrochlorothiazide...
Randomized Controlled Trial
Journal of clinical hypertension (Greenwich, Conn.). 2007 Jan;9(1):36-44. DOI:10.1111/j.1524-6175x.2007.5713.x 2007
Prevalence, treatment, and control of hypertension in primary care: gaps, trends, and opportunities [0.03%]
初级卫生保健中高血压的患病率、治疗和控制情况：差距、趋势及机遇
Robert J Petrella,Elizabeth P Merikle,Jared Jones
Robert J Petrella
Since most cases of hypertension are managed in family practice, estimates of the prevalence, treatment, and control in the primary care population are needed to adequately address the burden of hypertension in Canada as it has in other cou...
Beneficial effects of angiotensin II type 1 receptor blocker antihypertensive treatment on inflammation indices: the effect of smoking [0.03%]
血管紧张素Ⅱ受体拮抗剂降压治疗对炎症指标的有利影响及吸烟对该项作用的影响
Stella-Maria G Kyvelou,Gregory P Vyssoulis,Eva A Karpanou et al.
Stella-Maria G Kyvelou et al.
The effect of long-term angiotensin II type 1 receptor blocker (ARB) therapy on inflammation indices has not been fully investigated in a hypertensive population. The authors evaluated 323 consecutive nondiabetic patients (mean age, 57 year...
Economic analysis of a randomized trial of academic detailing interventions to improve use of antihypertensive medications [0.03%]
降压药物使用学术推广干预措施的随机试验经济学分析
Steven R Simon,Hector P Rodriguez,Sumit R Majumdar et al.
Steven R Simon et al.
The authors estimated the costs and cost savings of implementing a program of mailed practice guidelines and single-visit individual and group academic detailing interventions in a randomized controlled trial to improve the use of antihyper...